ResMed financials
$222.83+0.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | $1.43B | $1.42B | $1.34B | $1.35B | $1.29B | $1.28B | $1.22B | $1.22B | $1.20B | $1.16B | $1.10B |
| Gross profit | $869.5M | $898.8M | $886.5M | $828.6M | $829.4M | $773.9M | $758.9M | $724.9M | $715.5M | $692.8M | $655.2M | $609.0M |
| Gross margin | 59.4% | 62.8% | 62.3% | 62.0% | 61.5% | 59.9% | 59.2% | 59.2% | 58.5% | 57.9% | 56.3% | 55.2% |
| Operating income | $448.7M | $499.8M | $491.7M | $446.5M | $454.5M | $426.3M | $417.2M | $387.3M | $381.2M | $374.6M | $275.1M | $289.0M |
| Net income | $383.4M | $398.7M | $392.6M | $348.5M | $379.7M | $365.0M | $344.6M | $311.4M | $292.2M | $300.5M | $208.8M | $219.4M |
| Net margin | 26.2% | 27.9% | 27.6% | 26.1% | 28.2% | 28.3% | 26.9% | 25.4% | 23.9% | 25.1% | 18.0% | 19.9% |
| Diluted EPS | $2.64 | $2.74 | $2.68 | $2.37 | $2.58 | $2.48 | $2.34 | $2.11 | $1.98 | $2.04 | $1.42 | $1.49 |
| EBITDA | $493.5M | $558.8M | $547.5M | $510.0M | $518.2M | $469.9M | $463.7M | $432.0M | $381.2M | $418.1M | $384.1M | $333.9M |
| Operating cash flow | $454.6M | $554.1M | $339.7M | $457.3M | $538.8M | $578.7M | $308.6M | $325.5M | $440.1M | $402.0M | $272.8M | $286.3M |
| Free cash flow | $403.5M | $520.5M | $311.2M | $414.4M | $508.2M | $557.9M | $288.0M | $307.7M | $415.2M | $380.8M | $249.5M | $256.2M |
| Diluted shares | 145.2M | 145.7M | 146.4M | 146.9M | 147.1M | 147.2M | 147.5M | 147.6M | 147.7M | 147.5M | 147.5M | 147.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.47B | $1.66B | $1.42B | $1.38B | $1.21B | $932.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $659.4M | $664.1M | $663.8M | $668.6M | $668.3M | $673.0M |
| Total assets | $8.97B | $8.78B | $8.50B | $8.31B | $8.17B | $7.57B |
| Total liabilities | $2.38B | $2.29B | $2.18B | $2.19B | $2.21B | $2.02B |
| Shareholders' equity | $6.59B | $6.49B | $6.32B | $6.12B | $5.97B | $5.55B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology